ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 661

Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction

Magdalena Sroka1, Indranil Biswas1, Brian Shepherd1, Dat C Truong2, Harini Bagavant1 and Umesh S Deshmukh1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma, Norman, OK

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies, mouse model and salivary hypofunction, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Sjögren's Syndrome - Poster I: Translational Science

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Circulating autoantibodies reactive against Ro52 are detected in the sera of 70% of patients with Sjögren’s syndrome (SS), and their presence has been associated with higher severity of the disease. Previous work from our laboratory has demonstrated that interaction between anti-Ro52 and activated innate immunity induces salivary gland (SG) dysfunction in the New Zealand Mixed (NZM) 2758 strain of mice. This study was undertaken to investigate the mechanisms involved in anti-Ro52 mediated salivary gland dysfunction.

Methods: To determine the role of B cell epitope specificity in glandular dysfunction, NZM 2758 mice (5-10 per group) were immunized with recombinant fusion proteins representing the 3 structural domains of Ro52: Ring-B-Box (amino acids 16-123), Coiled-coil (amino acids 128-238) and SPRY (amino acids 268-465). Control mice were immunized with Maltose-binding protein (MBP). All immunization used Alum as the adjuvant. Antibody reactivity was analyzed by immunoprecipitation assay employing 35S-Met labeled Ro52, and by flow cytometry, using mouse ductal cell line SCA9-15. The ability of antibodies to penetrate live SCA9-15 cells was investigated by immunofluorescence. To determine end-organ susceptibility, anti-Ro52 serum generated in rabbits was passively transferred into either untreated or alum treated NZM2758 and lupus-prone NZM2328 mouse strains. SG function was assessed by measuring pilocarpine stimulated saliva.

Results: All groups of NZM2758 mice, except the MBP immunized control mice, generated IgG antibodies capable of immunoprecipitating whole Ro52. While antibodies in the sera from most of the coiled-coil immunized mice (7/8) penetrated live SCA9-15 cells, only 1/5 SPRY and 0/10 Ring-B-box immunized mice had cell penetrating antibodies. This antibody uptake was not dependent on the Fc gamma receptor expression. Only mice immunized with the coiled-coil domain showed a significant drop (p=0.0027) in saliva production. Passive transfer of rabbit anti-Ro52 readily induced SG dysfunction in NZM2758 mice, which was further amplified, if the mice were pretreated with alum. No such functional loss was observed in the lupus-prone NZM2328 mice.

Conclusion:  Our study demonstrates that anti-Ro52 mediated salivary gland dysfunction is regulated by antibody epitope specificity and the genetic susceptibility of the end-organ. Our data provides an explanation for the lack of concordance between the presence of anti-Ro52 and the extent of dry mouth observed in some patients. Thus, in SS patients, measuring the relative levels of anti-Ro52 domain reactive antibodies might be more informative than just determining the presence or absence of anti-Ro52.


Disclosure: M. Sroka, None; I. Biswas, None; B. Shepherd, None; D. C. Truong, None; H. Bagavant, None; U. S. Deshmukh, None.

To cite this abstract in AMA style:

Sroka M, Biswas I, Shepherd B, Truong DC, Bagavant H, Deshmukh US. Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/epitope-specificity-and-end-organ-susceptibility-dictates-anti-ro52-mediated-salivary-gland-dysfunction/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epitope-specificity-and-end-organ-susceptibility-dictates-anti-ro52-mediated-salivary-gland-dysfunction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology